Graft Versus Host Disease (GVHD)
Publications

Updated: March 2011

1. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers MDE. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant 11:945-955, 2005.
    Filipovich 2005 Biol Blood Marrow Transplant
2. Vogelsang GB. How I treat chronic graft-versus-host disease. Blood 95:1196-201, 2001.
    Vogelsang 2001 Blood
3. Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I, Lu J-G, Gajewski J, Durett A, Cleary K, Champlin R, Andersson BS, and Light S. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 95:83-89, 2000.
    Przepiorka 2000 Blood
4. Sullivan KM, Witherspoon RP, Storb R, Deeg HJ, Dahlberg S, Sanders JE, Appelbaum, FR, Doney KC, Weiden  P, Anasetti C, Loughran TP, Hill R, Shields A, Yee G, Shulman H, Nims J, Strom S, and Thomas ED. Alternating-Day Cyclosporine and Prednisone for Treatment of High-Risk Chronic Graft-v-Host Disease. Blood 72:555-561, 1998.
    Sullivan 1998 Blood
5. Abraham R, Szer J, Bardy P and Grigg A. Early cyclosporine taper in high-risk sibling allogeneic bone marrow transplants. Bone Marrow Transplantation 20:773-777, 1997.
    Abraham 1997 Bone Marrow Transplant
6. Przepiorka D, Weisdorf D, Martin P, Lingemann HG, Beatty P, Hows J, Thomas ED. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplantation 15(6):825-8, 1995.
    Not available